Osteonecrosis is a medical term meaning "bone death." It is caused by an inflammation of the hip joint due to a reduction in blood supply. This type of bone disease can have an extensive impact on the quality of life of individuals suffering from it, making the treatment of osteonecrosis extremely important.
Market Dynamics
High prevalence of osteonecrosis is expected to propel growth of the osteonecrosis treatment market. For instance, according to the study, ‘Epidemiology of osteonecrosis among older adults in Sweden’, published in Springer in January 2019, the 10-year risk of osteonecrosis was 0.4% and the incidence rate was 4.7 cases/10000 person-years. Moreover, high prevalence of osteoporosis is also expected to aid in growth of the osteonecrosis treatment market. For instance, according to a study published online in February 2020 in the Journal of Clinical Endocrinology & Metabolism, for denosumab-treated women with postmenopausal osteoporosis, invasive oral procedures and events (OPEs), including dental implants, tooth extraction, natural tooth loss, scaling/root planning, and jaw surgery, are common and associated with osteonecrosis of the jaw.
High prevalence of cancer is expected to offer lucrative growth opportunities for players in the osteonecrosis treatment market. For instance, in December 2020, a study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and published in JAMA Oncology, found that 2.8 percent of patients on average develop osteonecrosis of the jaw, within three years of starting a common treatment for cancer that has spread to the bone. Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.
Among regions, North America is expected to witness significant growth in the osteonecrosis treatment market, owing to high prevalence of cancer. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Competitive Analysis
Major players operating in the osteonecrosis treatment market include, Bone Health, Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd.
Major players operating in the osteonecrosis treatment market are focused on approval and launch of new products to expand their product portfolio. For instance, in December 2020, Bone Health’s OsteoBoost received the U.S FDA’s Breakthrough Device Designation to reduce the risk of osteoporosis.
In-depth Report on Osteonecrosis Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/ongoing-insight/osteonecrosis-treatment-market-1490
No comments:
Post a Comment